Khojah and colleagues conducted a randomized controlled clinical trial to investigate the efficacy of RES therapy in treating RA, wherein they found that RES effectively reduces the levels of TNF-α, IL-1β, IL-6, monocyte chemoattractant protein 1, and soluble receptor activator of NF-κB ligand in both serum and joint tissues (138). The gene discussed is TNF; the disease is rheumatoid arthritis.